#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13456	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2095	637.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1662	1662	T	779	T	713	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13456	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2095	637.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1396	1396	C	795	C	725	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25016	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3735	668.2	0	.	n	.	0	C543T	SNP	543	543	C	966	966	T	780	T,C	717,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25016	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3735	668.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1760	1760	A	861	A,G	793,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25016	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3735	668.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2394	2394	C	803	C,T	729,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25016	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3735	668.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2468	2468	A	783	A	727	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25016	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3735	668.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3020	3020	C	786	C,A	719,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1902	folP	855	855	99.88	folP.l15.c30.ctg.1	1560	121.4	1	SNP	p	R229S	1	.	.	685	687	AGC	976	978	AGC	203;203;201	A;G;C,T	184;187;182,1	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4902	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3306	147.6	0	.	p	.	0	V290I	NONSYN	868	870	GTT	1184	1186	ATT	115;116;115	A,G;T;T	107,1;108;106	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4902	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3306	147.6	1	SNP	p	S91F	0	.	.	271	273	TCC	587	589	TCC	176;177;177	T;C;C	166;164;164	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4902	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3306	147.6	1	SNP	p	D95N	0	.	.	283	285	GAC	599	601	GAC	174;177;178	G;A;C	162;161;163	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4902	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3306	147.6	1	SNP	p	D95G	0	.	.	283	285	GAC	599	601	GAC	174;177;178	G;A;C	162;161;163	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1536	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1324	115.0	1	SNP	p	G45D	1	.	.	133	135	GAC	494	496	GAC	205;210;212	G;A,G;C	193;197,1;201	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	792	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	1177	67.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1498	1500	ATC	185;185;181	A,G;T;C	162,1;160;159	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1651	1653	GCA	190;191;193	G,A;C,T;A,G	172,1;167,1;171,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2134	2136	ATT	183;183;181	A;T;T	173;173;172	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	1	SNP	p	D86N	0	.	.	256	258	GAC	604	606	GAC	193;193;194	G;A;C	172;171;177	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	1	SNP	p	S87R	0	.	.	259	261	AGT	607	609	AGT	195;194;197	A,C;G;T	179,1;180;178	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	1	SNP	p	S87I	0	.	.	259	261	AGT	607	609	AGT	195;194;197	A,C;G;T	179,1;180;178	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	1	SNP	p	S87W	0	.	.	259	261	AGT	607	609	AGT	195;194;197	A,C;G;T	179,1;180;178	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4216	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2964	141.8	1	SNP	p	S88P	0	.	.	262	264	TCC	610	612	TCC	200;199;202	T;C;C	183;183;189	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3914	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2582	150.9	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2067	2069	AAC	162;165;165	A;A;C	146;145;150	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3914	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2582	150.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1464	1466	GGC	209;205;204	G;G;C	194;189;188	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1232	1234	GCA	220;218;217	G;C;A	206;205;207	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1235	1237	ATC	219;217;215	A;T;C	207;204;203	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1247	1249	GTG	213;214;214	G;T;G	202;201;199	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1247	1249	GTG	213;214;214	G;T;G	202;201;199	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1751	1753	ACC	188;188;188	A;C;C	172;173;173	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1805	1807	GCG	170;171;167	G;C;G	155;138;138	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1805	1807	GCG	170;171;167	G;C;G	155;138;138	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1928	1930	GGT	198;192;190	G;G;T	183;179;174	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1937	1939	GGC	184;183;180	G;G;C	171;170;168	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3788	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2402	157.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1955	1957	CCG	183;183;177	C;C;G	135;154;130	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5420	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3067	175.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2052	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1800	113.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	559	559	C	140	C	125	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	104	93.27	porB1a.l15.c30.ctg.1	684	27.2	0	.	p	.	0	M18T	NONSYN	52	54	ATG	342	344	ACG	91;90;87	A;C;G	80;79;78	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	104	93.27	porB1a.l15.c30.ctg.1	684	27.2	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	384	386	CAA	52;50;47	C;A;A	45;43;39	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	104	93.27	porB1a.l15.c30.ctg.1	684	27.2	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	390	392	TAC	32;32;27	T;A;C	30;29;27	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	174	93.68	porB1a.l15.c30.ctg.2	218	33.9	0	.	p	.	0	A251V	NONSYN	751	753	GCG	82	84	GTA	36;35;35	G;T,C;A,G	28;27,1;27,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	174	93.68	porB1a.l15.c30.ctg.2	218	33.9	0	.	p	.	0	S271T	NONSYN	811	813	TCG	142	144	ACT	50;49;49	A,T;C;T	44,1;44;43	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	174	93.68	porB1a.l15.c30.ctg.2	218	33.9	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	148	150	GAT	42;41;36	G,C;A;T	37,1;37;32	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	174	93.68	porB1a.l15.c30.ctg.2	218	33.9	0	.	p	.	0	D276N	NONSYN	826	828	GAT	157	159	AAC	34;35;35	A,G;A;C	30,1;32;31	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	296	porB1a	984	174	93.68	porB1a.l15.c30.ctg.2	218	33.9	0	.	p	.	0	N277H	NONSYN	829	831	AAC	160	162	CAC	36;36;36	C,T;A;C	31,1;32;31	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	2644	porB1b	1041	1041	99.04	porB1b.l15.c17.ctg.1	1514	172.9	0	.	p	.	0	S36Y	NONSYN	106	108	TCT	391	393	TAT	228;224;223	T;A;T	208;207;205	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	2644	porB1b	1041	1041	99.04	porB1b.l15.c17.ctg.1	1514	172.9	0	.	p	.	0	K120D	NONSYN	358	360	AAG	643	645	GAC	229;230;230	G;A;C	211;211;213	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	2644	porB1b	1041	1041	99.04	porB1b.l15.c17.ctg.1	1514	172.9	0	.	p	.	0	K208del	DEL	622	622	A	906	906	A	228	A	210	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	2644	porB1b	1041	1041	99.04	porB1b.l15.c17.ctg.1	1514	172.9	0	.	p	.	0	G211S	NONSYN	631	633	GGC	913	915	AGC	232;227;226	A,G;G;C,A	219,1;215;214,1	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	2644	porB1b	1041	1041	99.04	porB1b.l15.c17.ctg.1	1514	172.9	0	.	p	.	0	S216I	NONSYN	646	648	AGC	928	930	ATC	217;216;215	A;T;C	199;195;198	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	2644	porB1b	1041	1041	99.04	porB1b.l15.c17.ctg.1	1514	172.9	0	.	p	.	0	I333T	NONSYN	997	999	ATC	1279	1281	ACC	199;199;196	A;C,T;C	180;180,1;179	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10408	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4884	212.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1966	1968	CAT	234;232;228	C;A;T	215;212;205	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1060	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1152	91.7	1	SNP	p	V57M	0	.	.	169	171	GTG	632	634	GTG	208;211;208	G,C;T;G	194,1;197;194	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
